Skip to main content

Stroke and Mortality Significantly reduced by blood pressure–lowering treatment for elderly patient


An international trial looking at the benefits of giving blood pressure-lowering medication to those aged 80 and over has stopped early, after reserachers observed significant reductions in overall mortality in those receiving treatment.
The 3,845 patient Hypertension in the Very Elderly Trial (HYVET) is the largest ever clinical trial to look at the effects of lowering blood pressure solely in those aged 80 and over. Preliminary results of the trial, which is co-ordinated by scientists from Imperial College, suggest that lowering blood pressure significantly reduces both stroke and mortality in the over-80s.
A number of earlier trials had demonstrated that reducing blood pressure in the under-80s reduces stroke and cardiovascular events. However, previous smaller and inconclusive studies also suggested that whilst lowering blood pressure in those aged 80 or over reduced the number of strokes, it did not reduce - and even increased - total mortality.
Patients with high blood pressure from across the world were randomised for the double-blind, placebo-controlled trial, which began in 2001. Patients were given either placebo or a low dose diuretic (indapamide 1.5mg SR) and an additional ACE inhibitor (perindopril), in tablet form once a day.
Emeritus Professor Chris Bulpitt, HYVET Principal Investigator from the Care of the Elderly Department at Imperial College, said, "It was not clear prior to our study whether the over-80s would benefit from blood pressure-lowering medication in the same way as younger people. Our results are great news for people in this age group because they suggest that where they have high blood pressure, such treatment can cut their chances of dying as well as stroke."
The steering committee of HYVET accepted on 12 July 2007 the recommendation of its Data Safety Moniroting Board that the trial should be stopped.
Definitive figures will not be available until all the data has been collected. Results will then be published in the peer-reviewed scientific press.
Over the next few months all HYVET patients will be seen for a final visit, where all patients on trial medication will be offered the option of switching to active indapamide 1.5mg SR-based antihypertensive treatment. Prior to their final visit, all patients are advised to stay on their existing drugs until they see their trial physician.
HYVET was co-ordinated by scientists from Imperial College London, working with colleagues around the world. the main trial was funded by both the British Heart Foundation and by the Institut de Recherches Internationales Servier.

Source : Imperial College London, Faculty of Medicine